Loading clinical trials...
Loading clinical trials...
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ruijin hospital
Shanghai, Shanghai Municipality, China
Start Date
September 28, 2022
Primary Completion Date
December 1, 2024
Completion Date
December 1, 2026
Last Updated
February 24, 2023
320
ESTIMATED participants
peripheral blood collection
PROCEDURE
Lead Sponsor
Ruijin Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions